HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kushner, B. H. Search for Related Content PubMed PubMed Citation Articles by Kushner, B. H.

Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies*

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York

Neuroblastoma stands out among pediatric solid tumors because of its relative frequency, intriguing natural history, prognostic biologic features, and therapeutic challenges. It is the most common extracranial pediatric solid tumor and the most common neoplasm in infancy; >90% of the 600 cases diagnosed annually in the United States are in children 5 y old. Screening programs of infants show that many cases escape detection because of spontaneous regression or maturation into benign lesions. Origin from precursors of the sympathetic nervous system accounts for (a) primary sites in adrenal glands and in paraspinal locations from neck to pelvis and (b) high urinary levels of catecholamines in >90% of cases. This embryonal neoplasm often encases vascular structures and, unlike most solid cancers, usually presents with substantial metastatic disease (bone, bone marrow, lymph nodes, liver; spread to lung or brain is rare). Hence, defining disease status requires CT (or MRI), bone scan, metaiodobenzylguanidine (MIBG) scan, bone marrow tests, and urine catecholamine measurements. The natural history is strikingly variable but is largely predictable from clinical and biologic features. The latter are critical for distinguishing low-risk (90% survival) from high-risk (25%–30% survival) subsets, allowing identification of patients who, despite a favorable clinical profile (e.g., localized tumor), are likely to develop lethal metastatic disease, versus patients who have an ominous clinical profile (e.g., widespread disease) but are likely to survive, sometimes with little or no cytotoxic therapy.

Key Words: neuroblastoma • embryonal neoplasm • metaiodobenzylguanidine • pediatrics

Related articles in JNM:

This Month in JNM

JNM 2004 45: 13A-14A. [Full Text]  

This article has been cited by other articles:

				D Mullassery, C Dominici, E C Jesudason, H P McDowell, and P D Losty Neuroblastoma: contemporary management Arch. Dis. Child. Ed. Pract., December 1, 2009; 94(6): 177 - 185. [Full Text] [PDF]

				D. R. Taggart, M. M. Han, A. Quach, S. Groshen, W. Ye, J. G. Villablanca, H. A. Jackson, C. Mari Aparici, D. Carlson, J. Maris, et al. Comparison of Iodine-123 Metaiodobenzylguanidine (MIBG) Scan and [18F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therapy for Relapsed Neuroblastoma J. Clin. Oncol., November 10, 2009; 27(32): 5343 - 5349. [Abstract] [Full Text] [PDF]

				B. H. Kushner, K. Kramer, S. Modak, and N.-KongV. Cheung Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma J. Clin. Oncol., March 1, 2009; 27(7): 1041 - 1046. [Abstract] [Full Text] [PDF]

				K. Rozovsky, B. Z. Koplewitz, Y. Krausz, S. Revel-Vilk, M. Weintraub, R. Chisin, and M. Klein Added Value of SPECT/CT for Correlation of MIBG Scintigraphy and Diagnostic CT in Neuroblastoma and Pheochromocytoma Am. J. Roentgenol., April 1, 2008; 190(4): 1085 - 1090. [Abstract] [Full Text] [PDF]

				K. J.L Fernandes, J. G Toma, and F. D Miller Multipotent skin-derived precursors: adult neural crest-related precursors with therapeutic potential Phil Trans R Soc B, January 12, 2008; 363(1489): 185 - 198. [Abstract] [Full Text] [PDF]

				M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly In vivo Imaging and Quantitation of Adoptively Transferred Human Antigen-Specific T Cells Transduced to Express a Human Norepinephrine Transporter Gene Cancer Res., December 15, 2007; 67(24): 11959 - 11969. [Abstract] [Full Text] [PDF]

				C. Franzius, K. Hermann, M. Weckesser, K. Kopka, K. U. Juergens, J. Vormoor, and O. Schober Whole-Body PET/CT with 11C-Meta-Hydroxyephedrine in Tumors of the Sympathetic Nervous System: Feasibility Study and Comparison with 123I-MIBG SPECT/CT J. Nucl. Med., October 1, 2006; 47(10): 1635 - 1642. [Abstract] [Full Text] [PDF]

				C. K. McGarvey, K. Applegate, N. D. Lee, and D. K. Sokol False-Positive Metaiodobenzylguanidine Scan for Neuroblastoma in a Child With Opsoclonus-Myoclonus Syndrome Treated With Adrenocorticotropic Hormone (ACTH) J Child Neurol, July 1, 2006; 21(7): 606 - 610. [Abstract] [PDF]

				G. Cecchetto, V. Mosseri, B. De Bernardi, P. Helardot, T. Monclair, E. Costa, E. Horcher, S. Neuenschwander, P. Toma, A. Rizzo, et al. Surgical Risk Factors in Primary Surgery for Localized Neuroblastoma: The LNESG1 Study of the European International Society of Pediatric Oncology Neuroblastoma Group J. Clin. Oncol., November 20, 2005; 23(33): 8483 - 8489. [Abstract] [Full Text] [PDF]